Project Grant R35NS137159

Award Date 12/18/24
Completion Date 11/30/32
Dollars Obligated $2.3M
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award of $385,500 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports the development of a novel inducible and multiplexed dual gene regulation CRISPR system to study neuronal activity and regeneration. The award will fund research at The Leland Stanford Junior University (Stanford University) to engineer a system capable of simultaneous...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,001,864 to Harvard University to investigate the subcellular mechanisms underlying the selective vulnerability of specific neuron subtypes in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will quantitatively study the localization of RNA, proteins, and translational regulation in the synapses and soma of vulnerable corticospinal neurons (CSN) and...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to develop a novel cellular model for investigating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will directly convert patient-derived fibroblasts into neurons, preserving the epigenetic age of the starting cells, in order to...
The National Institute on Aging (NIA) awarded a $619,681 Project Grant (CFDA 93.866 - Aging Research) to The Leland Stanford Junior University (Stanford University) to develop innovative tools for studying the complex genetic interactions underlying Alzheimer's disease (AD) pathogenesis. The project, titled "Combinatorial Perturbation with Multi-Omics Readout to Dissect Etiology of Alzheimer's Disease Using Stem Cell and In Vivo Models", will create a toolkit combining gene-editing...
This federal Project Grant award, valued at $131,027.00, was provided by the National Institute on Aging under the Aging Research program (CFDA 93.866) to The Leland Stanford Junior University. The award aims to study neuronal proteostasis, the maintenance of protein health, during brain aging and Alzheimer's disease (AD). The key products and services to be delivered under this grant include: Conducting in vivo experiments using a novel bioorthogonal non-canonical amino acid tagging (BONCAT)...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $1,138,538 to Mayo Clinic Jacksonville to expand research into the mechanisms underlying frontotemporal lobar degeneration (FTLD), which causes frontotemporal dementia (FTD) and is genetically linked to amyotrophic lateral sclerosis (ALS). The research aims to investigate key...
This Project Grant award of $374,349 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports the development and optimization of a new animal model for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The goal is to create a mouse model that accurately recapitulates the human disease spectrum by incorporating an acetylation-mimicking...
This Project Grant award of $598,952 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support the development of a novel human stem cell-derived multi-cellular model to study the developmental processes underlying spinal cord midline crossing of axons. The awardee, The Leland Stanford Junior University, will generate and functionally characterize organoids...
This federal Project Grant award, valued at $129,717.00 and awarded on January 20, 2025 by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to investigate the role of neutrophil heterogeneity and molecular mechanisms in driving amyotrophic lateral sclerosis (ALS). The research aims to identify subpopulations of neutrophils and associated mechanisms...
This $195,570 federal Project Grant award was made by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The award supports research by The Regents of the University of California, San Francisco (UCSF) to investigate the role of the molecular co-chaperone DNAJC7 in preventing the aggregation of misfolded proteins associated with neurodegenerative diseases such as...

This federal Project Grant award of $2,307,075, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders, supports an ambitious research program at Stanford University focused on defining novel mechanisms of human neurodegenerative diseases and translating those findings into new therapeutic strategies.

The key objectives of this grant include: 1) Conducting genome-wide modifier screens in human cells using CRISPR/Cas9 to identify regulators of neurodegenerative disease proteins like ataxin 2, 2) Elucidating the role of cryptic splicing events in ALS pathogenesis, and 3) Applying single-cell sequencing technology to study mouse and human spinal cord samples to reveal new markers of motor neuron subtypes. This multi-faceted research effort aims to drive fundamental scientific advances that can inform the development of innovative therapies for devastating neurological conditions like ALS, FTD, and Parkinson's disease. The grant period runs from December 2024 through November 2032.

Generated 8/5/25, 5:17 AM